Tim Nichols, MD

Professor of Medicine and Pathology, Division of Cardiology
Director, Francis Owen Blood Research Laboratory

Specialty Areas

Basic and translational research in hemostasis and thrombosis utilizing models of hemophilia, von Willebrand disease, and atherosclerosis.

Education and Experience

B.S. Stanford University, 1974; MD: Virginia Commonwealth University, 1978; Resident: University of North Carolina, Internal Medicine, 1978-1981; Chief Resident: University of North Carolina, Internal Medicine, 1981-1982; Fellow: University of North Carolina, Cardiology, 1982-1985; Board Certified Internal Medicine, 1982; Board Certified Cardiology, 1985; Board Certified Internal Medicine/Interventional Cardiology, 2001.

Research and Clinical Interests

As an internationally recognized clinical investigator, Dr. Nichols’ current research focuses on improving treatments for patients with inherited bleeding disorders. His expertise in vascular biology research focuses on the role of von Willebrand factor in arterial thrombosis. Dr. Nichols also has an active hemostasis research program to develop new therapies for hemophilia A and hemophilia B, especially those complicated by inhibitory antibodies (anti-drug antibodies).

Dr. Nichols’ other special interests include coronary artery disease and thrombosis, cardiac catheterization, coronary angioplasty, and novel ultrasound imaging techniques.

Selected Bibliography

Superior human hepatocyte transduction with adeno-associated virus vector serotype 7. Shao W, Pei X, Cui C, Askew C, Dobbins A, Chen X, Abajas YL, Gerber DA, Samulski RJ, Nichols TC and Li C. Gene Ther. 2019;10.1038/s41434-019-0104-5.

Research_and_Practice_in_Thrombosis_and_Haemostasis p. OC 51.5 | Recombinant Canine and Human FXa- I16LProvide Safe and Efficacious Hemostasis during Major Bleeding Events in Hemophilia A Dogs with High- titer Inhibitory Anti- FVIII Antibodies. Nichols TC, Merricks EP, Wimsey LA, Pittman D, Miao C, Arruda VA and Camire R. Research_and_Practice_in_Thrombosis_and_Haemostasis – Abstracts for 2019 XXVII ISTH Meeting. 2019:109.

An Observational Study from Long-Term AAV Re-administration in Two Hemophilia Dogs. Sun J, Shao W, Chen X, Merricks EP, Wimsey L, Abajas YL, Niemeyer GP, Lothrop CD, Monahan PE, Samulski RJ, Nichols TC and Li C. Mol Ther Methods Clin Dev. 2018;10:257-267.

Complete correction of hemophilia B phenotype by FIX-Padua skeletal muscle gene therapy in an inhibitor-prone dog model. French RA, Samelson-Jones BJ, Niemeyer GP, Lothrop CD, Jr., Merricks EP, Nichols TC and Arruda VR. Blood Adv. 2018;2:505-508.

Influence of diabetes on the foreign body response to nitric oxide-releasing implants. Soto RJ, Merricks EP, Bellinger DA, Nichols TC and Schoenfisch MH. Biomaterials. 2018;157:76-85.

Oral Tolerance Induction in Hemophilia B Dogs Fed with Transplastomic Lettuce. Herzog RW, Nichols TC, Su J, Zhang B, Sherman A, Merricks EP, Raymer R, Perrin GQ, Häger M, Wiinberg B, Daniell H. Mol Ther. 2017 Feb 1;25(2):512-522.

Translational data from adeno-associated virus-mediated gene therapy of hemophilia B in dogs. Nichols TC, Whitford MH, Arruda VR, Stedman HH, Kay MA, High KA. Hum Gene Ther Clin Dev. 2015 Mar;26(1):5-14.

Non-invasive in Vivo Characterization of Human Carotid Plaques with Acoustic Radiation Force Impulse Ultrasound: Comparison with Histology after Endarterectomy. Czernuszewicz TJ, Homeister JW, Caughey MC, Farber MA, Fulton JJ, Ford PF, Marston WA, Vallabhaneni R, Nichols TC, Gallippi CM. Ultrasound Med Biol. 2015 Mar;41(3):685-97.

Portal vein delivery of viral vectors for gene therapy for hemophilia. Sherman A, Schlachterman A, Cooper M, Merricks EP, Raymer RA, Bellinger DA, Herzog RW, Nichols TC. Methods Mol Biol. 2014;1114:413-26.

Targeted Disruption of LDLR Causes Hypercholesterolemia and Atherosclerosis in Yucatan Miniature Pigs. Davis BT, Wang XJ, Rohret JA, Struzynski JT, Merricks EP, Bellinger DA, Rohret FA, Nichols TC, Rogers CS. PLoS One. 2014 Apr 1;9(4):e93457.

View list of publications on PubMed.